Your English writing platform
Discover LudwigSuggestions(2)
Exact(28)
Dinaciclib MK-79655, formerly SCH727965), a small-molecule cyclin-dependent kinase inhibitor, has demonstrated antitumor activity in phase I studies with solid-tumor patients.
Even so, phase I studies with different IGF1R antibodies demonstrated remarkable responses in a subset of Ewing's sarcoma patients [11], [12], [13].
Overall the human phase I studies with G3139 demonstrated good efficacy with low toxicity.
The sample sizes were based on experience from previous similar Phase I studies with other compounds.
Recently, two phase I studies with MAG-CPT have been performed.
Objective To quantify the frequency and seriousness of adverse events in non-oncology phase I studies with healthy participants.
Similar(29)
In the absence of dose-limiting toxicity (DLT), we decided to stop at a dose of 38 mg/m/week, a greater dose than previous assessments in phase-I studies with weekly docetaxel alone [ 24].
We decided to stop the accrual early at a level of weekly docetaxel 38 mg/m, that being a greater dose than in previous assessments, from both phase-I studies with weekly Docetaxel alone and with Docetaxel concomitant with standard radiotherapy.
Concurrent weekly Docetaxel and Tomotherapy are feasible; we did not reach a maximum tolerated dose, because no life-threatening toxicity was observed, stopping the accrual at a level of weekly docetaxel 38 mg/m, a greater dose than in previous assessments, from both phase-I studies with weekly docetaxel alone and with Docetaxel concomitant with standard radiotherapy.
I studied with Ernie Barnes, Peter Mak, with Enrico Navarra.
Back then I studied with the television on.
Write better and faster with AI suggestions while staying true to your unique style.
Since I tried Ludwig back in 2017, I have been constantly using it in both editing and translation. Ever since, I suggest it to my translators at ProSciEditing.

Justyna Jupowicz-Kozak
CEO of Professional Science Editing for Scientists @ prosciediting.com